Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a shareholder update on March 13, 2026, authored by CEO Jim Joyce, outlining the company's strategic initiatives including a potential merger with a Nasdaq-listed company and the sale of certain assets. The company, which develops dialysis-like therapies for cardiovascular disease and cancer, has faced challenges in capitalizing its endeavors after withdrawing a registration statement for an uplist to Nasdaq financing.
Joyce, who previously founded Aethlon Medical and led the development of the FDA-cleared Hemopurifier, highlighted Sigyn's CardioDialysis platform. This technology targets cholesterol-transporting lipoproteins and inflammatory molecules, aiming to reduce major adverse cardiovascular events (MACE). Unlike lipoprotein apheresis, limited to fewer than 60 specialized centers in the U.S., CardioDialysis is designed for use on dialysis machines at over 7,500 clinics nationwide. The company also sees potential in treating sepsis, traumatic brain injury, and other inflammatory conditions based on in vitro study results.
Regarding the failed uplist, Joyce explained that Nasdaq requested review of investors prior to SEC approval of the registration statement, creating a regulatory catch-22. Consequently, Sigyn withdrew the offering and is now exploring alternative strategies to preserve shareholder value. Among these is a potential merger with a Nasdaq-listed company at risk of failing the $5 million minimum market value of listed securities (MVLS) requirement. The company is also considering the sale of certain assets, including its traumatic brain injury indication, which has recently gained value.
Joyce encouraged shareholders to review his January 15th shareholder update for further details on strategies to reduce dilution. He noted that while share price and exchange listing do not affect the therapeutic potential of Sigyn's technologies, they impact the company's ability to raise capital without harming shareholder value. As of March 11, 2026, Sigyn had 2,330,042 shares outstanding.
Sigyn's pipeline also includes ImmunePrep to optimize immunotherapeutic antibody delivery, ChemoPrep to enhance targeted chemotherapy, and ChemoPure to reduce chemotherapy toxicity. The company's CardioDialysis device is positioned as a first-in-industry medical device for cardiovascular disease, the leading cause of death globally.
